30.11.2018 HumanOptics AG  DE000A1MMCR6

DGAP-Adhoc: HumanOptics AG: Capital increase from authorized capital planned with exclusion of subscription rights; sustainable strengthening of equity base through conversion of liabilities


 

DGAP-Ad-hoc: HumanOptics AG / Key word(s): Capital Increase/Letter of Intent
HumanOptics AG: Capital increase from authorized capital planned with exclusion of subscription rights; sustainable strengthening of equity base through conversion of liabilities

30-Nov-2018 / 12:44 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


HumanOptics AG and its majority shareholder Medipart AG with seat in Unterägeri/Switzerland today agreed to carry out a capital increase from the authorized capital under exclusion of subscription rights in order to strengthen the equity capital on a sustained basis.

The share capital of the company, currently amounting to EUR 3,090,000.00, is to be increased by a nominal amount of EUR 50,000.00 to EUR 3,140,000.00 by issuing 50,000 new bearer shares with a pro rata amount of the share capital of EUR 1.00 per new share against contribution in kind. In consideration of the stock exchange price, the issue price shall be EUR 20.00 per new share, which shall thus be above the average closing price (arithmetic mean) of the HumanOptics share in XETRA trading on the Frankfurt Stock Exchange on the ten trading days in the period from 16 to 29 November 2018 in the amount of EUR 19.26. Medipart AG shall be admitted to subscribe the 50,000 new shares as a contribution in kind against contribution of a nominal amount of EUR 1,000,000.00 of its loan claims against HumanOptics AG.

The partial contribution of loan receivables will substantially reduce liabilities without affecting liquidity, reduce interest charges for the company and increase equity. The partial contribution of the loan receivables thus represents a significant contribution to the sustained strengthening of the company's equity base.

Contact: HumanOptics AG Investor Relations Spardorfer Str. 150 91054 Erlangen Telefon: +49 (0) 9131 50665-0 E-Mail: [email protected]


30-Nov-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: HumanOptics AG
Spardorfer Str. 150
91054 Erlangen
Germany
Phone: +49 (0)9131 - 50665-60
Fax: +49 (0)9131 - 50665-93
E-mail: [email protected]
Internet: www.humanoptics.de
ISIN: DE000A1MMCR6
WKN: A1MMCR
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Stuttgart

 
End of Announcement DGAP News Service

753243  30-Nov-2018 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=753243&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 10,51 11,56 11,04 10,68 9,36 10,20 0,00
EBITDA1,2 0,82 0,54 -1,28 -1,27 -1,90 0,80 0,00
EBITDA-Marge3 7,80 4,67 -11,59 -11,89 -20,30 7,84 0,00
EBIT1,4 0,33 0,13 -1,71 -1,76 -2,42 0,34 0,00
EBIT-Marge5 3,14 1,12 -15,49 -16,48 -25,86 3,33 0,00
Jahresüberschuss1 0,16 0,03 -1,78 -1,89 -2,57 -0,25 0,00
Netto-Marge6 1,52 0,26 -16,12 -17,70 -27,46 -2,45 0,00
Cashflow1,7 0,99 0,53 -1,30 -1,84 -1,53 0,30 0,00
Ergebnis je Aktie8 0,05 0,01 -0,58 -0,60 -0,74 -0,07 0,29
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2019 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ebner Stolz

INVESTOR-INFORMATIONEN
©boersengefluester.de
HumanOptics
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A1MMCR 9,000 Halten 31,39
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
21,43 34,23 0,63 -57,33
KBV KCV KUV EV/EBITDA
12,06 - 3,35 -18,76
Dividende '19 in € Dividende '20e in € Div.-Rendite '20e
in %
Hauptversammlung
0,00 0,00 0,00 18.12.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
- 03.12.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-0,73% -6,46% 8,43% 17,65%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu HumanOptics AG  ISIN: DE000A1MMCR6 können Sie bei DGAP abrufen

Medtech , A1MMCR , H9O1 , FWB:H9O1